Cenedella.de

Patient Advocate since 1977.


Leave a comment

Regulation in Germany….and we aren’t talking about soccer :)

The current regulation in Germany made it difficult for German companies to apply to get a license for Cannabis cultivation.

** And that is why the process is now held up in litigation in the German court system. One of the unsuccessful bidders has sued over the requirements and the entire application process is on hold, with any potential awards being made in Q1 or Q2 2018 at the earliest.

What is the most popular model for cannabis cultivation in Germany, so far?
The cultivation in Germany is currently not legal, done outdoors and indoors and hidden from sight and smell as best as possible.

There is no legal German cultivation currently allowed, even for patients with valid medical approvals.

There is small cultivation being done as part of R+D projects in Universities and Scientific companies.

Regarding joint ventures: How do foreign cannabis companies usually work together with German companies?

In various ways, based on their business objectives and strategy. Three examples are:

Canopy Growth Corporation purchased a German firm Medcann, which became Spektrum Germany. They are considered by many to be the premier cannabis firm in Germany today.

Maricann of Canada purchased a former cargo facility in Dresden for 3€ million and is ramping up their European operations, adding staff, and building out their new European headquarters.

An international firm is currently in discussions with a German startup, to establish a joint venture partnership which will make news around the world. This partnership should be made public in early 2018 and will be ground-breaking.

To cover the demand of medical cannabis Germany is importing from other countries. Supply is coming especially from Canada. Which other countries might be relevant cannabis suppliers in the future?

Canada and The Netherlands are currently the only authorized countries to import into Germany. Supplies are seriously constrained and with Canada becoming a legal recreational country in July 2018, the supply bottlenecks are expected to be exacerbated well into 2019.

Tilray has announced plans to establish a cultivation facility in Portugal to supply the German, and European market in the future.

The governments of Greece, Israel, South Africa, Australia, Chile, Uruguay, and others are currently working with private sector companies to establish their own cultivation and export capabilities.

Germany, with twice the population of California, is a key market for any serious player in the global cannabis industry.

What is your personal opinion about the current German regulation. What will be the next major steps?

Regulation and taxation is always better than the illegality and violence of the black market. Always.

Thank God for the German court system which has brought legalized medical marijuana to the people, if it were up to the politicians, we would still be waiting.

Now the intelligent implementation of recreational laws need to be established to legalize the plant which has been used for thousands of years.

Reducing opioid deaths, helping certain people with their medical conditions, and enabling super-straight people to enjoy jazz music are just some of the benefits of a world where ganja is regulated, safe, and profitable.

The flower of cannabis will always have a place in the market, but in the next years we will see an increase in other forms of cannabis that are more easily consumed….edibles, oils, salves and the like. As a result, GMP (Good Manufacturing Process) certification is going to become very important for those wanting to establish a quality product in the German and European markets.

And if we look at the European Cannabis market. Which major market trends do you identify?

1- Everyone seems to be focusing on cultivation, but this segment is expected to become a commodity item in the near term. Companies may want to look at establishing a product line including “finished products with GMP certification” to become a leading force in this market.

2- At some point the insurance companies are going to become true partners in providing cannabis therapies to the German pharmacies. This will happen as a result of cost-savings and health-benefits realized vs. the current pharmaceuticals offered to patients.

3- In the words of Peter Tosh:
“Legalize it.”

The Berlin Peace Accords (attached) calls for an end to the 80 year World War On Cannabis, and we agree. Legal, regulated, safe and non-violent recreational marijuana markets have already been established in the US and Uruguay, with Canada and others joining the party in 2018.

Pharmaceutical companies don’t like it, Beer companies don’t like it (although the owners of Corona beer just invested $250 million in Canopy Growth’s cannabis business last month) and some short-sighted politicians don’t like it. But “We the People…” have made our opinions known and the calls for a rational, legal, safe and non-violent cannabis market is just a few moments away here in the center of Europe.

These are historic times, Germany is leading the world in many ways, 2018 will be an interesting year.

peace,
Phil

Advertisements


Leave a comment

Germany’s largest legal cannabis plantation – by VICE Magazine

https://www.vice.com/de/article/qvjge5/weed-aus-dem-atombunker-dieser-typ-baut-deutschlands-grosste-legale-cannabis-plantage

http://www.bunker-ppd.de/

Germany’s largest legal cannabis plantation
Tim Geyer
Oct. 17 2017, 3:20 pm
Because of grass dealings, Christoph Roßner had already been in prison for five months. Today he works with Bavarian politicians.

This is not really a loose work place, even if grass is to be cultivated, says Christoph Roßner. The Atombunker, before which he stands, is squeezed between car parks and fields in the Allgäu countryside like a stranded oil tank. Here, from the former Fliegerhorst Memmingerberg NATO would have led the nuclear counterattack, had the Cold War escalated. Today the entrepreneur wants to breed cannabis in the bunker. Green haze instead of black rain – within sight of a federal police station and with the blessing of the Bavarian government. Since the beginning of the year, cannabis is legal on prescription in Germany and Rossner’s sentiment is that of a brewer’s owner after the end of the prohibition: “We have the chance to become one of the biggest players in the international cannabis market.”

Alone for 2015, the German Monitoring Center for Drugs and Drug Abuse (DBDD) counts almost five million Germans who have consumed cannabis at least once during the last twelve months. The dark figure should be even higher. Activists and businessmen have taken this first step towards legalization. Christoph Roßner is both. And also looks like this: black jacket over black sweater, the gray hair tamed to the horse tail. Business in the front, party in the back.

One of the many lock gates between the individual bunkers
From the war machine to the grass factory

The bunker, a 50-meter-long, 15-meter high colossus, with its aerial storms acts like a medieval fortress. From 1985, the Luftwaffe soldiers of the Jagdbombersgeschwader 34 were sitting here, servicing the control systems for the nearby rocket silos. “This bunker is safer than a nuclear waste disposal site, but we want to grow plants here,” says the 47-year-old. He has previously registered with the neighboring Federal Police Station on the visit of the journalists.

The Panzertor groans aside. 175 tons of hardened steel, eight meters wide, nearly one meter thick. A siren howls like a submarine on a dive. Through the opening one reaches the actual bunker, which surrounds the outer wall as the reactor coherent of Chernobyl. Then another lock door, another 30 centimeters of steel. Later, 15 employees of Roßner’s company Bunker PPD, which he wants to adjust, will change the street clothes against overalls without bags and scan their fingerprints. The few, the income, will be nothing to take with. Roßner leads past former team rooms and the radio center, a five-meter-thick steel-concrete ceiling above us. You go ducked, even though you do not have to.

But no matter how many nights Roßner is working on his business plans, in the end others decide: the Federal Institute for Drugs and Medical Devices and the Bundespiumstelle, which is subordinate to him. Anyone who wants to produce or use drugs in Germany must either talk to them or seek a good lawyer. But once the TÜV seal of the Panzertür has expired, once the officials discover a tiny mistake in a request: the bureaucrats are editing Roßner, the changing Würgreiz for CSU politicians, so meticulously as if they Franz Josef Strauss’ last will.

Where the radio had previously been monitored, a cannabis laboratory could soon be available
From activist to cannabis entrepreneur

Roßner knows this. For the last three decades he has been working on the legalization of cannabis. Two key experiences are the reason: at 17 he smokes his first joint. He notes: Kiffen helps him to curb his hyperactivity. A year later a steel carrier crushed his left shoulder during his training as an industrial mechanic. Against the chronic pain smokes Roßner cannabis. To this day, now on recipe. “If you like, I’m just tight,” he says. In 1994, a friend of Roßner, who suffers from epilepsy, finds out that marijuana dampens his attacks. Roessner’s sister also suffered from epilepsy. For them, this knowledge comes too late. Two years before, she committed suicide. “I could have helped her,” says Rossner.

From this moment on, he is on a mission: He is worried about marijuana to help others, he says. “Illegal research” he calls this. At that time, as today, cannabis is prohibited by law in Germany. It is only since 1 March 2017 that doctors can prescribe – even without the hard-to-obtain exemption. Although in 1994, the Federal Constitutional Court ruled that a small quantity of cannabis can be carried with no prescription – depending on the federal state, between five and ten grams – this verdict does not, however, protect against criminal prosecution. This is what the courts alone decide. Roessner also knew about the risk, especially in Bavaria, When it is rumored that he is running a kind of private hemp pharmacy, more and more people are coming. Rheumatics, neurodermatitis, chemotherapy patients. And some policemen.

If at any time the electricity should fail, Roßner can take advantage of four diesel generators to supply his cannabis lantern with light
Roßner is sentenced: two years and one month. He spends five months in prison and four in therapy. It’s been 17 years now. When he rages, he knocks again at his doorstep. Still, people who have pain are coming. Roßner does not do any illegal business, he continues to believe in the medical benefits of cannabis. Together with the Chair of Chemistry at the Technical University of Munich and the University of British Columbia, he is currently preparing a study to investigate the effects of the most important medicinal hemp varieties and to develop quality standards for them. 150 patients he wants to provide cannabis from his bunker. Will the study and the necessary hemp cultivation be approved, this would be his first decisive step to enter the medical cannabis market. The study is intended to prove that he, the ex-prisoner, is serious.

Politicians, investors and business bosses listen to him

By working with the universities, Roßner hopes that the newly established state-owned cannabis agency will choose him to produce state-certified grass. The agency is to provide patients with marijuana from Germany and is looking for producers all over Europe. In addition to Rossner, other German entrepreneurs are also applying, for example SensHemp from Berlin and Hanf AG from Hamburg. 2,000 kilograms per year, the agency estimates, would have to grow on German plantings in 2021 and 2022 to supply all patients. Roßner believes that German patients need six times a year: over 12 tonnes of grass. If no one has to apply for an exemption, but only needs a prescription, more patients will take this step, he is sure. In addition, it would not be worth it to build a plant worth several million euros. But without permission for the study, he could set up his bunker to a very unpleasant country house.

Plantation air could soon flow through the ventilation towers
Just a strong CSU conservative helps him with his plan. Franz Josef Pschierer, State Secretary in the Bavarian Ministry of Economic Affairs, will bring him together with entrepreneurs and politicians from Bavaria in 2016. Roßner tells them about the unused economic potential, possible tax revenues and savings in the police and courts. “Without the help of the Bavarian government, no one would listen to me,” he says. He is now planning his cannabis breeding plant with ThyssenKrupp – and is holding talks with internationally active hedge funds. If they invest in it, the Free State of Bavaria could subsidize its business with about a quarter of a million euros. From tax money. Marijuana sponsored by Horst Seehofer.

In many places in the bunker the soldiers have left something behind
While Roßner sketched his battle plan for the next months, we descend deeper into the airtight crypt. There is neither mobile phone reception nor spiderwebs. Comic paintings on the walls testify to what the soldiers were busy with when they were bored to wait for the Third World War. In one room there are vault chambers, large as overseas containers. Here the mother plants could grow. “Lamps clean, connect ventilation, let’s go,” says Roßner, “more perfect conditions than here you will find nowhere.” A high-security laboratory is to move into the former squadron headquarters. Here, chemists could clone potent cannabis varieties. Next to it stands an industrial furnace, in which former toxins were destroyed at 900 degrees. In the future, the most serious of these will be burned. A few security doors: the space for the cuttings. “We start with 80 different varieties,” Roßner says self-confidently, as if he had the approval already.

In these cabinets Roßner wants to breed young plants
Race with the Dutch

Sometimes Christoph Rossner would ask the same as the early fans of Cherry Coke or anal whitening: When will the backward-looking Germans finally understand what the Americans have long been celebrating? In 29 out of 50 US states , medical cannabis has been allowed or grass has been fully legalized. In 2016, the industry generated sales of 6.7 billion US dollars . Until it is so far in Germany, Rossner will still have to smoke a few blunts on the recipe.

At the beginning of the year, he was sitting with his lawyers to prepare a lawsuit against the Federal Institute for Drugs, he tells us as we step out of the darkness of the bunker. The agency has asked potential medical producers that they have already grown, processed and delivered at least 50 kilograms over the last three years. How is he to apply, if exactly that in Germany so far was illegal, Roßner curses. It is not easy to get a mission in Germany for something that does not really exist at all.

Meanwhile, the authorities want to improve – a small victory, but Rossner is running out of time. The Dutch company Sensi Seeds systematically purchases small cannabis producers in the USA and is now pushing into the German market. Roßner does not want to be bought up. His research project will start in March, followed by commercial operations. He wants to make money himself and make the world a bit better with nothing but a few plants from a Bavarian atomic bomb.

Follow VICE on Facebook , Instagram and Snapchat .


Leave a comment

German Medical Marijuana Patients face mounting struggles to secure their medicine, while companies from the US and elsewhere are forbidden to help. #shameful

 

 

Criticism of the cannabis lawThe struggle for cannabis

In March the policy was celebrated: cannabis on prescription – a breakthrough! But many patients are dissatisfied. The funds do not want to pay the costs, the pharmacies are struggling with supply bottlenecks. The fight for hemp is in full swing.

By Christin Jordan, SWR

Magdalena Sebelka has epilepsy, ADHD and severe asthma. She has already tried a few medications – helped only cannabis.

As with the 10th of March, cannabis can be prescribed for prescription and bought at the pharmacy. The new law makes it possible for the funds to pay the costs. As far as the theory. Practically, around 1000 people in Germany have already been allowed to buy and consume cannabis products in pharmacies with an exception. But they had to pay it out of their own pocket.

In severe diseases such as cancer, Crohn’s disease, multiple sclerosis or pain patients, medical cannabis is used for therapy. The hemp blossoms are imported, certified cultivating plants are available in Canada, the USA and the Netherlands.

Fighting with the health insurance companies

The young woman has an exception license, issued by the Federal Institute for Drugs and Medical Devices. So far she has received a prescription from the doctor and has been able to buy and consume hemp flowers – at her own expense. Your hope in the law was great. Then the disappointment: your doctor prescribes her the drug, but she must continue to pay for it herself. The checkout refuses to take over the costs.

According to the law, the first regulation has to be submitted and approved by a health insurance company at the health insurance – but this is rejected by Sebelkas Kasse. It is not proven that cannabis is the only active ingredient that helps her.

Many affected parties also report in Internet forums about the struggle with the coffers. Your guess: It’s about money. Because cannabino therapy is expensive – an average patient costs around 9000 euros per year.

Cannabis as a last resort

The leading association of statutory health insurance funds rejects the charge of wanting to save costs. The funds would have to adhere to the law whereby cannabis products can only be used as cash-in-service if no other therapy helps.

In addition, since the entry into force of the Act on 10th March, 1000 cost-taking has already been approved by the funds, so the number of legal cannabis users has risen significantly.

But why do people with an old exception permit like Magda Sebelka not automatically claim to be covered by the health insurance funds provided for by the new law? According to Speaker Florian Lanz, there is no legal basis for this. There was no provision for the existence of existing populations for the old patients; every regulation had to be examined separately, which could also reject cash applications – as in many other therapies.

Legal, but expensive

One gram of cannabis flowers costs 25 euros in the pharmacy – a lot of money for those who are self-paying. Sebelka reports that since the introduction of the law the price of medical cannabis products has almost doubled. The reason was that the pharmacists had to calculate the goods according to the German drug regulation. The German Association of German Pharmacists’ Associations rejects this – cannabis has always had to be treated as a medicinal product like any other medicinal plant. “I can not understand the alleged price increases,” explains deputy press singer Ursula Sellerberg.

Limited cannabis

But patients who have accepted the cost of taking over the costs can still not breathe. Medical cannabis is currently scarce, the foreign suppliers can not meet the needs. “Of ten cannabis medicines, I can only offer one at the moment”, says the chief pharmacist Martin Schmidt. He can only provide his regular customers – if new cash patients with cannabis recipes came, they probably went empty. Schmidt sees the fault with the policy: “The law was a quick shot, one had to have thought about where these quantities of medical cannabis products should come from.”

A quick solution is not in sight. Germany wants to build a state cannabis agency and control cannabis cultivation – however only two years. Until then, Magda Sebelka may perhaps consume at the expense of the cash box cannabis – she complains in an urgent case against the decision.

Your opinion about:Kritik am Gesetz für legalen Cannabiskonsum

July 26, 2017 – 11:22

A hemp plant

In March the policy was celebrated: cannabis on prescription – a breakthrough! But many patients are dissatisfied. The funds do not want to pay the costs, the pharmacies are struggling with supply bottlenecks. The fight for hemp is in full swing. By Christin Jordan.

Article on tagesschau.de

Comments

Finally legalize costs

Finally legalize, save money! There are arguments against it, but then one would have to honestly forbid alcohol etc.

What would the police finally release? You will not move the potatoes if you criminalize it. Consumption has been steadily increasing for years. We must pay the police.

The market regulates …

… the price and that is good so. And that the checkout does not pay is correct. I would not like to finance a cannabis as a cashier. Basta.

Simply laughable …

Delivery bottlenecks at something every 17 year old can grow. Welcome to Germany.
And what is the idea of ​​allowing hemp first when opiates do not have the desired effect?
Just look to Holland – the kids there are not as big as the one here – simply because it is nothing special – you can buy in the coffeeshop, nice to smoke there and then as after a beer to go home, the stub on the Way smoking and done.
The drilldown made here around the story is simply laughable.

Build yourself

If I was in a desperate situation would have a serious illness and would have to fight with bad pain, I would be mildly shed, whether the cultivation is illegal.
Then the just a seriously sick man in the jail are stuck …..

@ Ruffian

“I do not want to co-finance a cannabis as a cashier.” Basta. ”

I hope they stay healthy. My wife was not lucky enough, and cannabis is the only active ingredient of the (including).

@karawanke

“The market regulates the price”
The road price is around 10, – EUR per gram and thus far less than half as what pharmacies demand.

“And that the checkout does not pay is right.”
No it is not. The legal situation is clear and the coffers have to submit to this!

“I do not want to finance a cannabis as a cashier.”
And I do not want to co-finance your surgery and chemo if you get cancer, preferably by smoking. Or your physiotherapy when you break your bones while skiing. But I must. Therefore, your “desire” is irrelevant.

@ Karawanke

>>> I would like to co-finance no cannabis as a cashier. Basta.
,
Cannabis is cheaper and more effective than alternative products. Also less harmful / side effects than chemical drugs.
As a cashier, I would rather pay cannabis than an artificial, overpriced product of the pharmaceutical industry.

The only reasonable solution is

The free sale to all in pharmacies, or separate shops. Then there are also no bottlenecks. On the contrary, a new, lucrative industry for all parties would be created, decriminalizing consumers, thereby relieving the police / courts and generating tax revenues.

It is already disappointing

It is already disappointing to see how the health insurance companies are squirming, just not having to pay … what they actually have to do according to the law, so almost every complaint against social courts is also successful.

It’s damn cynical when one forces patients to be forced into illegality again.

Whoever can afford it and does not want to act illegally, can issue a private recipe. So what do you call two-class medicine ?!

Yes, I also like to see when my health insurance contributions are spent on safe and helpful substances like cannabis! To refuse a patient’s medicine is simply immoral (aka “is not at all!”).

Prices not traceable

“Because cannabino therapy is expensive – an average patient costs around 9000 euros per year.”

And what would be the cost if the legislator were to equate cannabis with the tobacco – 100 euros?

Looks to Uruguay

And learn how to do something like that!

Legal health insurance is called …

… the legislator defines the conditions, and that makes him very stringent and very concrete. Paragraph 12 of Book V of the Social Insurance Code states that
“(1) benefits must be sufficient, appropriate and economic, and must not exceed the extent of what is necessary.” Insured persons are not entitled to benefits which are not necessary or uneconomical And do not grant health insurance funds. ”
In this respect, the GKVs may only authorize if the conditions of § 31 (6) SGB V are fulfilled. In particular, no alternative recognized therapeutic method may be available for the purpose of use (cannabis is almost everywhere else).
To this extent, the hope of German consumers,

@karawanke

“I do not want to co-finance a cannabis as a cashier.” Basta. “… but the lush profit margins of the pharmaceutical industry … no further comment needed

Prices not traceable!

The pharmacy wants 25 €?
On the street the price is 10 to 12 €.

Who as a chronic patient illigal a Hanfzucht cabinet poses thereby long-term producer prices of under 3 € the gram realize.
On a large scale professionally cultivated hemp products would be spottbillig !!! “Pfennig Amounts” for the gram!

They would be cheaper than most pharma alternatives and the health insurance funds would be financially relieved by hemp medicine.

Earlier, hemp was grown on German fields. This was because of the fibers, but was the same kind.
Hemp cultivation is relatively easy: hemp is robust, needs little to no use of chemistry and the soil needs little preparation. For this purpose it is relatively dry-resistant (grows well on Moroccan fields).

The fact that we have supply bottlenecks and usurious prices is the only political failure!

@ Karawanke “no cannabis co-finance”

Aha?!

How is it with opioids? They finance you through your health insurance contributions on a grand scale.

Or benzodiazepines? A not insignificant proportion of the drug addicts are attributed to this drug. They also finance you.

What about amphetamines? You are funding Ritalin and others about your contributions.

What about cocaine derivatives? Lidocaine and other local anesthetics …

What I want to tell you: Many drug classes, which you know as an illigal drug, have at the same time a high medical potential, which has always been widely used.

The active ingredients in hemp also have high medical potential. And the side effects are relatively harmless compared to all the above active substance classes! These are facts, the medical world is largely in agreement. And although this is not in the sense of the pharmaceutical lobby.

From a scientific point of view, it is a scandal that a modern enlightened country like Germany so far does not use these drugs

@spetzki

Cent amounts per gram are nonsense! That would only go on the field so cheap and then the quality is not given. For medical purposes it is cultivated in enclosed spaces wherever it is allowed. There is the driving cost factor alone the current.

It is the GKV’s in Germany for a long time only around …

…Money.
Not only in patients who need cannabis, since other agents either do not help or have too much side effects.

Is not different with me.
My pain therapy costs around
2,662 € a year.
For cannabis it would be 3-4 times as expensive.
The big difference is that cannabis has much less side effects and is therefore less harmful to the body.
After all, I am talking about a lifelong application of the preparations.
At the moment I have to take Oxycodon acute (4 times daily).
With Hemp I need substantially less to zero.

But the coffers do not care.
Alone the regulation that if there is another means, cannabis not or difficult to maintain or even be bought at own expense, drives many people into the madness and ruin.

No, our health care system & The responsible politicians also take care of
the patient.

It’s just about money.

@ 11: 31 from OrwellAG – so please, it is not about the …

… Consumption of a killer who would like to have a intoxication.

It is a question of adopting a law that gives people free access to their medicine.

And then the cashiers are straining themselves with the simple assertion that there are substitute medications which the patient must take.
Or the patient has to pay himself.
The Otto-normal patient can not do this.
Especially since most people who need such a drug anyway can no longer work.

@ no idea


To be economical” “in particular, no alternative recognized method of healing may be available for the purpose of use (cannabis is almost everywhere else).”

Hemp is one of the oldest cultivated and medicinal plants of mankind.
This is not a new idea. And it is not an “alternative healing method”! This is not a Bachblütentee – hemp contains highly potent active ingredients.
They are well-known and well-researched active ingredients.
Hemp has been tried for decades to demonize (and still can not present any facts).
The fact is, in many cases, hemp should be the first choice, because:
– very low potential for side effects
– if done right
– unbeatable – great patient compliance. Many patients prefer a traditional herbal drug to a modern drug.

From the passages you quoted, I interpret that hemp medicine needs to be promoted more strongly.

@ Donidon: field went

One has to ask, of course, how the use of these drugs should develop in the long term.
I think: In the same as for all other active ingredients also: standardized medical products: tablets, drops, … suppositories 🙂

This would mean that the active ingredients are dissolved from the plant material and isolated and standardized products are produced therefrom.
For this application, the active ingredient content in the plant material may fluctuate smoothly.

And so “Pfennigsbeträge” can be realized.

If the hemp flower should have as much as possible reproducible concentrations of active ingredients, then you are right: you have to keep all parameters constant, including lighting, nutrient supply (via hydroponic systems), temperature and humidity.

It is not the best solution to leave the hemp flower to the patient. Because this self-medication (smoking, evaporating, baking cookies, …) is inaccurate and less effective than modern forms of administration.

11:49 by karawanke

“And that the cash box does not pay is correct, I would not like to finance a cannabis as cashier.” Basta. ”

Then I wish you heartfeltly that you will never get into the situation, that cannabis is the only way to live a certain human life and die later. My husband has ALS. Both (first and second) motoneuron are affected. Particularly painful are the muscle cramps. His doctor would prescribe in the cannabis, the cashier does not pay. For the other medicines, he has to reckon with enormous side effects, eg liver damage.

There are growing countries

There are more and more countries cunning and legalizing cannabis, why we have to make it more complicated than it is.
We leave it over pharmacies, health insurance and doctors, which is a bureaucracy.
Everyone is able to cultivate cannabis and it is made everywhere. So just legalize it and we save money and trouble.
This is a billion dollar market the D left. Cannabis has always been consumed. The purchase is as easy as buying biscuits.
This could create thousands of jobs in D, instead the pharmaceutical industry is supported, so they can sell their expensive preparations.
Even America has recognized this market. To ban a naturally growing plant and brewed beer, Baked liquor, & c. That’s funny!
D always notes it at the end!
I hope I ever experience the complete legalization!

“They are well-known and well-researched drugs.”

You should not write something, just to write something.
You can count yourself as an employee of a sawmill on one hand for an effective study for the treatment of diseases or even for the adjuvant use of dronabinol or nabilone. Evident studies, however, are a compelling basis for the preparation of therapiesand guidelines of the specialist companies.
In this respect, you can put your “facts” at least in health care in 99.5% of cases for the coming years, where the sun rarely has an opportunity to see them.
Because in exactly this relation, there are standardized procedures that are cheaper than cannabis on Rp. – and then we must prescribe this, The cash registers are not allowed to grant more expensive procedures and the patient can not claim them. That’s the way – and I do not want to be embarrassed to pay the bags of my patients myself.

We own one

We have an endocannabinoid system where the cannabinoids CBD, THC & Co. (over 100 exist) can dock. We also produce our own cannabinoids ourselves. However, since the research on cannabis has been suppressed for so long, studies are often lacking, and therefore the evidence. Look at all the people in the world to be scolded at the “Kiffer”. They are often better with the herb than with chemically produced “medicine”, the cannabis need only be determined, reaped, dried and taken.

As always, it is about maximizing profit, if patients have to suffer (see cancer medication). Not only does methadone show surprising results, cannabis too!

Doctor, “That makes psychoses!”
Patient: This with psychoses and cannabis is a hen and egg problem.

(Satire)
Is the risk of an induced psychosis very high when a “doctor” hears the word “cannabis”? Or was a psychosis VS ‘cannabis as medicine’, already there before?
(Satire off)

It is definitely harmful to health

Unfortunately, one must always keep in mind that the abuse of cannabis is a drug addictive and, just like drinking alcohol, is a serious damage to the nervous system.
Beautiful staining and Kiffer-Idyll bring there nothing.

Closing of the commentary function

Dear users,

Due to the high number of comments on meta.tagesschau.de, the news can not be commented at the moment.
We ask for your understanding.

Sincerely,
The Moderation


Leave a comment

The State of Cannabusiness in Germany

The State of Cannabusiness in Germany

As a cannabis business executive, you undoubtedly have been following some of the significant events happening in Europe and you have asked yourself: “How does this affect my plans?”

It may be the German government establishing a nationwide medical marijuana program, or news about the Canadian companies buying or merging with their European counterparts that has your attention. But you know the times are a changin’ and you might want to benefit from this historic moment in our Industry.

For those companies that already have a strategic international plan in place, the opportunities are boundless.  Germany, a nation with 2.5 times the population of California, is leading the way with the a national, Federal-government approved, medical marijuana law already in place, and numerous regional efforts to establish recreational use are getting off the ground as I write this column.

Having been an advocate in California during the medical marijuana legalization push of 1990s, and now living here in Germany as they build their own regulated marketplace, it has been fun to be involved. I’d now like to share some of the organizations that may be able to help you and your company, if Europe is indeed on your radar.

Das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) is the German federal government’s  Institute for Drugs and Medical Devices and is lead by Professor Dr. Karl Broich. Their website is www.bfarm.de and they are basically the cannabis bureau of Germany, charged with implementing the medical marijuana law.  Interestingly, they will also be the sole purchaser of foreign-produced medical marijuana products, and then oversee the distribution exclusively though licensed pharmacies.

So Germans will be going to their local pharmacy to obtain their medicine, which officially should be paid by their insurance company.  Of course, the details are still being worked out, and I know of at least two lawsuits against insurance companies not paying for their clients medicine.

Last month, the BfArM put out a call for bids for the first ten authorized grow licenses in the history of Germany.  Negotiations are underway and the winning bidders should be announced shortly.  We will keep you updated on this, and all important details emanating from Europe, in future columns.

The Deutscher Hanfverband (DHV) is the German Hemp Association in Berlin and a fantastic resource and advocacy organization. They have been instrumental in getting the country to this point and their website is https://hanfverband.de I highly recommend signing up for their newsletter (which can easily be translated.)  Their next big event is the Hanf Parade in Berlin in August which will bring together over 10,000 advocates calling for open access.

For companies that want to get serious about being in Europe, the best organization I know of is the German Trade and Investment office located in Berlin which is part of the German Federal Ministry of Economic Affairs. Their website is www.gtai.de.

Their knowledge is vast, their connections incredible, and there is no charge for their services. They want to make it easy for international companies in our space to help Germany build their regulated marketplace. They provide advanced research, site-selection, tax information. And.. they are just an email or phone call away.

Of course, there are a total of 51 independent states that make up Europe and 28 of those make up the European Union.  To some degree all of these countries are changing the way they treat medical marijuana and CBD products.

If you are looking for some opportunities in this region, I would suggest looking not only at Germany, but also The Netherlands, Spain, United Kingdom, Switzerland, and the Czech Republic. Although Israel is not in the EU region, their expertise, leading edge research, products and capabilities are to be noted.

Before concluding, I need to give a shout out to Mr. Alex Rogers and his team at ICBC Berlin who put together one of the best industry events I have ever attended.  Back in April, in Berlin, almost 1000 attendees and exhibitors from throughout the world gathered to share information, make connections and close business deals.

Congressman Dana Rohrabacher, chairman of the Cannabis Caucus in the U.S. House of Representatives, was the keynote speaker and shared stories on his German ancestry, his first meeting with Ronald Reagan, and why legalizing our plant makes sense in so many ways.

Tommy Chong was also in attendance, was way coherent, and meeting him was definitely one of my personal highlights.  Yes, I admit it, I listened to his albums way back in 1971.

So I wish you a productive, successful and fun month ahead as we collectively take the next steps to “Make Cannabis Great Again” here in Europe, and wherever you are reading this in the world.

About The Author:


Leave a comment

German researchers seek 25,000 marijuana users for study

http://www.ibtimes.co.uk/pot-smokers-wanted-german-researchers-seek-25000-marijuana-users-study-1618629

German researchers are hoping to get government backing for a new study that would see the recruitment of 25,000 recreational marijuana smokers.

The Research Initiative on Cannabis Consumption are seeking government approval to analyse the cannabis users in order to understand the effects of the drug after several years of use.

Their application is aimed at conducting a “Scientific Study on Cannabis Sequences for Mentally Healthy Adult Consumers” they say.

Germany legalised marijuana for medicinal purposes earlier in 2017 with new powers given to doctors to prescribe the drug to seriously ill patients at their discretion.

This, researchers say, paves the way for a new study analysing the longer-term effects of the drug.

Cannabis for recreational use is still illegal, but that hasn’t stopped 2,000 people already signing up for the study, say the researchers.

The group announced plans to begin the study in November 2016 saying it wanted to analyse the mental effects on those addicted to the drug.

“In Germany several million people regularly get high on cannabis,” wrote lawyer and chief executive of the project Marko Dörre in a statement released after the plans were submitted.

“It is time that science becomes more engaged with recreational use.”

Marijuana
German researchers are hunting for 25,000 cannabis smokers for a new study.Reuters/John Vizcaino

As part of the study, those selected would be permitted to pick up 30 grams of pharmaceutical cannabis, usually reserved for medical patients, on a monthly basis.

Researchers are prohibiting anyone under 18, first-time marijuana smokers, as well as candidates with high-risk of addiction or psychiatric problems, from taking part in the study.

Before the new act on the Amendment of Narcotics Regulations passed earlier this year, only around 1,000 people with serious medical conditions were permitted to use cannabis.

“With the law implemented in March changing controlled substance regulations, the German parliament took on a new risk assessment of cannabis,” said Dörre.

“The new assessment will also benefit science.”

The BfArM declined to comment to Tagesspiegel as to whether it had in fact received the application or the chances of it being approved.


Leave a comment

The German government finally passed its legalization framework for medical cannabis consumption in March 2017. The country’s market is expected to record modest growth with its high 82 million population and a policy that allows prescriptions to be paid through health insurance plans, …MOTLEY FOOL article

Which Top Marijuana Company Will Capture Germany?

The German government finally passed its legalization framework for medical cannabis consumption in March 2017. The country’s market is expected to record modest growth with its high 82 million population and a policy that allows prescriptions to be paid through health insurance plans, thus potentially encouraging patients to explore medical cannabis health benefits.

Local marijuana producers with vast experience in mass growing of high quality product and hungry to capture the lucrative €12 – €15 a gram (roughly C$17 – C$21.75 per gram) German medical cannabis market, have been taking positions in growing their international business portfolios.

Some of the top local growers have already established footprints in Germany, but which among the local players is likely to gain significant traction in the new market?

Canopy Growth Corp

The local market leader, Canopy Growth Corp. (TSX:WEED) has already made a significant investment in Germany. The company acquired MedCann GmbH Pharma & Nutraceuticals (MedCann) back in November 2016. MedCann, a distributor, has successfully placed Canopy’s Tweed branded cannabis strains into German pharmacies.

The German distribution model strictly  confines cannabis sales to the pharmacy distribution model and no direct sales shall be allowed. Since all sales shall take the wholesale distribution channel, Canopy is already at a first mover advantage in this market.

Canopy has indicated that it is interested in producing cannabis locally in Germany with the expansion of the local program. With Germany expecting to launch a domestic cannabis cultivation initiative by 2019, Canopy is likely to try broadening its expansion program in the country.

Aphria Inc.

Aphria Inc. (TSX:APH) has recently announced an international expansion program that is currently focused on the United States market, and has committed $25 million to an investment in Florida. Its not yet clear whether it intends to make serious investments in the new German market, but it has been eyeing this market for some time.

Although it had not yet made any formal engagements in Germany by January 2017, the CEO Vic Neufeld, in an interview with the Midas Letter openly stated that Germany has been very much on Aphria’s radar, and the company once engaged in dialogue with two different organisations pertaining the German market.

However, Aphria has been very cautious in their Canada and U.S. expansion programs so far. It seems the company has a slow-but-sure approach to doing business as its Canadian operations have shown, so I do not expect an overly vigorous and aggressive German expansion program from them.

Aurora Cannabis Inc.

One of the fastest growing and most aggressive marijuana producers, Aurora Cannabis Inc.(TSXV:ACB), has recently announced a $75 million convertible debenture offering which is likely to close on April 26, 2017, with a clear intent of using the funds to “aggressively pursue international expansion opportunities,” says CEO Terry Booth.

The company believes the $185 million cash position gives them the strongest cash balance “in the global cannabis sector,” and Aurora wants to play a leading role “in multiple emerging global cannabis markets.” 

Its most likely Aurora may attempt a German expansion route. Given the company’s growth style, it goes big on ventures and seeks aggressive expansion. These traits have seen it emerging to become a serious top contender in the Canadian marijuana space in a very short time.

Most noteworthy, Aurora is already listed on the Frankfurt Stock Exchange in Germany and raising expansion funds locally may be relatively easier.

Investor takeaway.

Its not yet clear who among these top marijuana companies may become a serious investor in Germany, but Canopy already commands a serious lead.

There are other serious Canadian contenders to the German market, like the soon-to-be-listed Maricann Group Inc, which is already trying to acquire an 800,000 square foot facility and likely seeking a cultivation license in Germany, and  CanniMed Therapeutics and the Cronos Group who already have distribution relationships in the European country.

However, there will be competition from Netherlands entities too, but the market may not be that big enough to support massive investment as yet. Canadian growers who manage to capture the infant German market may be rewarded though, as they will gain first mover advantages into the opening European market.

According to Google, “Marijuana” has been a more popular search term in Canada lately than our very own Justin Trudeau. And, not surprisingly, marijuana stocks have been the most popular topic for Motley Fool Canada readers for some time…and for good reason! However, not all “pot stocks” are created equal. That’s why we’ve created our premium report “Motley Fool Canada: 3 Marijuana Stock Tips for Investors Today.” Discover how you can gain access to the 3 stocks we believe investors should focus on in this premium Stock Advisor Canada report by clicking here now!


Leave a comment

The Cannabis Agency is a specialist area in the Department of Admission 4 (Special Therapies and Traditional Medicines) in the BfArM

http://www.bfarm.de/DE/Bundesopiumstelle/Cannabis/Cannabisagentur/_node.html

The Act on the Amendment of Drugs and Other Provisions, which entered into force on 10 March 2017, has expanded the scope for the prescription of cannabis medicines. The Act provides for the establishment of a government agency, the so-called cannabis agency, in accordance with the provisions of the United Nations Unity Treaty of 1961 on United Nations drugs. This will control and control the cultivation of cannabis for medical purposes in Germany.

Until cannabis is available for medical purposes from German cultivation, the demand is still covered by imports, for which the cannabis agency is not responsible (further information – see Bundesopiumstelle ).

The Cannabis Agency is a specialist area in the Department of Admission 4 (Special Therapies and Traditional Medicines) in the BfArM . It controls cultivation, harvesting, processing, quality testing, storage, packaging as well as delivery to wholesalers and pharmacists or manufacturers. The cannabis agency will take possession of the cannabis for medical purposes after the harvest.

The harvest is not transported to the BfArM , it is not stored there, nor is it redistributed from there. These steps will be located spatially at the respective construction companies or other commissioned companies.

The cultivation is therefore not carried out in the BfArM or by the BfArM itself, but by companies selected in a Europe-wide tender procedure and commissioned by the cannabis agency. The procedure takes into account all drug and narcotic drug requirements.

The tender procedure has now been published in the Official Journal of the European Union.
The following link leads to the tender documents: Supplement to the Official Journal of the European Union

Communication in connection with the tendering procedure takes place exclusively through the electronic award platform.

Cannabis will be grown exclusively for medical purposes. It is therefore a medicine. Only cannabis grown according to the guidelines of the Good Agricultural and Collection Practice (GACP ) will be used, which corresponds to the specifications of the Monograph “Cannabis Blossoms” ( DAB ) and the Requirements of the other relevant monographs and guidelines. This ensures the availability of cannabis for medical purposes in reproducible quality in accordance with drug laws. The cannabis for medical purposes is also subject to the provisions of the law on narcotic drugs.

The cannabis agency will set a manufacturer’s fee and sell the cannabis to cannabis drug manufacturers, wholesalers or pharmacies. The cannabis agency is not allowed to make any profits or surpluses. In the case of pricing, however, the personnel and material costs incurred by the BfArM are taken into account. However, the cannabis agency has no influence on the actual sales price in the pharmacy. The distribution channels of manufacturers and dealers will comply with the legal regulations and are thus identical with the regulations for the distribution of other drugs containing narcotic drugs.

Here you can find information about the cannabis agency and the cannabis cultivation of cannabis controlled by the cannabis agency for medical purposes:

Why must a so-called cannabis agency be established?
Where is the cannabis agency located?
What are the tasks of the cannabis agency?
What are the foundations of the tendering procedure?
How do I participate in the tender procedure?
Can you ask questions about the tender procedure?
How is the quality of the cannabis cultured in Germany to be used in the future?